Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2025

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy

RMD Open 2025;11:e005-21 Doi: 10.1136/rmdopen-2025-005521

Winthrop KL,

Klaff J,

Penn SK,

Liu Y,

García C,

Mysler E,

Wells AF,

Bu X,

Fish I,

Chen M,

Cunningham AL

Most patients vaccinated with RZV while using UPA 15mg QD and background MTX achieved satisfactory humoral and cell-mediated immune responses to recombinant zoster vaccine (RZV) at Weeks 4, 16 and 60. Winthrop et al. evaluated the immunogenicity of RZV through Week 60 in patients with RA who were receiving UPA 15mg QD and background MTX.

Keywords:

March 2025

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Res Ther. 2025;27:23. doi: 10.1186/s13075-024-03441-3

Kim TH,

Bu X,

Song IH,

Wung P,

Kato K,

Shmagel A

Van den Bosch et al. reported that upadacitinib 15 mg once daily led to sustained improvement in nr-axSpA over two years, including disease activity, pain, and quality of life. The study reports that 57.1% achieved ASAS40 response at week 104, with no new safety signals identified.